Core Viewpoint - The company Koyuan Pharmaceutical (301281) has significantly revised its net profit forecast for 2025, expecting a decline of 70% to 80% compared to the previous year due to a lawsuit involving its subsidiary, Lino Pharmaceutical. Financial Performance - The revised forecast for net profit attributable to shareholders is between 12.09 million yuan and 18.13 million yuan, down from the previous estimate of 27.20 million yuan to 39.29 million yuan, which represented a decline of 35% to 55% year-on-year [1][2] - The non-recurring net profit remains unchanged at between 20.12 million yuan and 29.06 million yuan [1][2] Legal Issues - Lino Pharmaceutical received a civil judgment from the Jiangsu Province court, requiring it to pay 16.11 million yuan in compensation related to a contract dispute with Jiangsu Saibang Pharmaceutical [1][3] - This judgment is considered an event that requires adjustment to the financial statements, leading to an increase in non-operating expenses by approximately 16.11 million yuan, which will reduce the net profit attributable to shareholders [3] Operational Challenges - Due to the contract dispute, one of Lino Pharmaceutical's bank accounts has been frozen, with 57 million yuan in funds affected, representing 4.19% of the company's latest audited net assets attributable to shareholders [6] - Koyuan Pharmaceutical primarily engages in the research, production, and sales of chemical raw materials and their formulations, along with intermediate business [6] Market Activity - In November 2025, Koyuan Pharmaceutical announced the termination of its acquisition of Hongjitang, initially planned to purchase 99.42% of the shares from Lino Investment Holding Group and others [6] - The decision to terminate the acquisition was made after careful consideration of changes in the overall market environment, aiming to protect the long-term interests of all shareholders [6]
子公司遭索赔！科源制药下修业绩预告